Magnetic resonance imaging with gadolinium enhancement in renal failure: A need for caution

International Journal of Dermatology

Volumn 47, Issue 9, 2008, Pages 947-949

  Gulati, Abha ^a,b   Harwood, Catherine A ^a   Raftery, Martin ^a   Cerio, Rino ^a   Ashman, Neil ^a   Proby, Charlotte A ^a  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b Institute of Cell and Molecular Science   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COLLAGEN; CREATININE; GADOLINIUM; MUCIN; RAPAMYCIN; THALIDOMIDE;

ADULT; ARTICLE; ASIAN; BRAIN HEMANGIOMA; BRAIN SURGERY; CASE REPORT; CELL PROLIFERATION; CLINICAL EXAMINATION; CONNECTIVE TISSUE DISEASE; CONTRACTURE; CONTRAST ENHANCEMENT; CREATININE BLOOD LEVEL; DAILY LIFE ACTIVITY; DENDRITIC CELL; DERMATOLOGY; DISEASE COURSE; DISEASE DURATION; DRUG TREATMENT FAILURE; ELASTIC FIBER; FIBROBLAST; FOOT EDEMA; FOOT PAIN; GLOMERULUS FILTRATION RATE; HAND EDEMA; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; JOINT STIFFNESS; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; MEDICAL DECISION MAKING; NEPHRECTOMY; NEPHROGENIC FIBROSING DERMOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT REFERRAL; PHYSIOTHERAPY; PUVA; RANGE OF MOTION; SYMPTOM; THROMBOPHILIA; VON HIPPEL LINDAU DISEASE;

ADULT; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; NEPHRECTOMY; NEPHROGENIC FIBROSING DERMOPATHY; RENAL DIALYSIS; RISK ASSESSMENT; SAFETY MANAGEMENT; VON HIPPEL-LINDAU DISEASE;

EID: 50149090196     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2008.03655.x     Document Type: Article

References (11)

1. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1001.
2. + cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: A new pathogenic hypothesis. Br J Dermatol 2004; 150: 1050-1052.
3. Swaminathan S, Ahmed I, McCarthy J. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006; 145: 234-235.
4. Cowper SE. Nephrogenic fibrosing dermopathy: The first six years. Curr Opin Rheumatol 2003; 15: 785-790.
5. Broome D, Girguis M, Baron P, et al. Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. Am J Roentgenol 2007; 188: 586-592.
6. Grobner T. Gadolinium -a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis. Nephrol Dial Transplant 2006; 21: 1104-1108.
7. Khurana A, Runge VM, Narayanan M, et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). Invest Radiol 2007; 42: 139-145.
8. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007; 242: 647-649.
9. Saitoh T, Hayasakah K, Tanaka Y, et al. Dialyzability of gadodiamide in haemodialysis patients. Radiat Med 2006; 24: 445-451.
10. Boyd AS, Zic JA, Abraham J. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56: 27-30.
11. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 21-26.